Parent Artery Reconstruction for Cerebral Aneurysms Using a Novel Flow Diverter With Surface Modification

The investigation is a prospective, multi-center, single arm clinical study. The trial is anticipated to last from March 2023 to January 2025 with 143 subjects recruited in around 10 China centers. The population for this study is subjects with wide-necked intracranial aneurysms who are suitable candidates for flow diverter implantation. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be enrolled after offering informed consent form. The study consists of six visits including preoperative screening, operation date, 7days or at discharge, 30 days, 180 days, and 1 year. The primary endpoint was successful aneurysm occlusion at one year post-procedure.

Inclusion criteria

• Age 18 years to 75 years, male or non-pregnant female.
• Unruptured wide-necked cerebral aneurysms confirmed by preoperative imaging (Wide-necked is defined as width ≥ 4 mm or a dome-to-neck ratio < 2).
• Parent vessel with a diameter range of 1.75-6.0 mm.
• Those who voluntarily participate in the study and sign informed consent form.

Exclusion criteria

• Subject with target aneurysms are blood blister-like aneurysms, pseudoaneurysms, arteriovenous malformation, moyamoya disease-related aneurysm, or multiple aneurysms that cannot be treated with a single stent.
• Severe arteriosclerosis or tortuosity of intracranial artery, and the device is difficult to reach the target vessel.
• Subject with target aneurysm previously treated with craniotomy or other endovascular interventional therapy.
• Known sensitivity to antiplatelet medications, anticoagulant medications, radiographic contrast agents, anesthetic, nickel, platinum-tungsten alloy, platinum-iridium alloy, and poly-N-[Tris(hydroxymethyl)methyl] acrylamide (poly-NTMA).
• Severe respiratory system, liver and kidney diseases (such as creatinine ≥ 3.0 mg/dL (except dialysis)) or blood coagulation disorders before operation.
• Platelet count is less than 100×109/L, international normalized ratio (INR) is more than 1.5.
• Hospitalized surgical treatment within the previous 30 days or planned within the next 180 days after operation.
• Severe neurological deficit that renders the patient incapable of living independently (modified Rankin score ≥3).
• The survival expectation is less than 1 year.
• All subjects who are participating in other drug/medical device clinical trials and have not completed the programme requirements
• Inapplicable for this study at the investigators' viewpoints.